{"entity":{"id":"nct07108127","kind":"trial","name":"Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced","aka":["NePHera"],"tldr":"A phase 2 trial in colorectal cancer, run by Peking Union Medical College Hospital, now recruiting.","summary":"Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer is a phase 2, interventional study registered as NCT07108127 by Peking Union Medical College Hospital, with a registry enrolment figure of 24 participants, started 2025-06-20 and due to reach its primary completion in 2026-12-01. Interventions recorded: Trastuzumab biosimilars and pertuzumab biosimilars plus XELOX. Conditions listed: Rectal Cancer; HER2-positive. Primary outcome: CR. Colorectal eligibility wording from the registry: \"Patients with rectal cancer confirmed by histology or cytology; locally advanced (cT3/T4, N+, distance from the lower edge of the tumor to the anal verge ≤ 12 cm) rectal adenocarcinoma (using the 8th edition of the AJCC TNM staging);\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07108127","url":"https://clinicaltrials.gov/study/NCT07108127"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","her2-amplified-colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07108127","phase":"2","setting":"Phase II Clinical Study on the Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer","sponsor":"Peking Union Medical College Hospital","participation":[{"nct":"NCT07108127","source":"https://clinicaltrials.gov/study/NCT07108127","fetchedAt":"2026-10-07T16:55:27.525Z","studySha256":"b1a699d02846a93f26496d62f30524a1bac52182ba3e88ec53fd463df19beedd","overallStatus":"RECRUITING","lastUpdatePosted":"2025-08-06","leadSponsor":"Peking Union Medical College Hospital","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":24,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-06-20","startedType":"actual","enrolled":24,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07108127/","neighbours":{"cancer":[{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}